.png)
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Phase III
Oncology
Subscribe to our newsletter to receive the latest case studies.
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Phase III
Oncology
A mid-size biopharmaceutical company was 18 months from launching a therapy for a rare oncologic disease with no prior approved treatments.
To support payer discussions and market adoption, the team needed credible, published evidence demonstrating disease burden, unmet need, and real-world impact.
The client engaged Alkemi to design and execute a coordinated evidence generation strategy to define market need and strengthen launch readiness.
1. Leveraged large claims datasets to quantify economic burden and healthcare utilization in the United States.
2. Designed and published national patient and provider preference studies to document burden, care patterns, and unmet need.
3. Developed a targeted patient engagement and recruitment strategy to support participation in real-world evidence studies.
Build publishable, payer-relevant evidence before launch.
"We appreciate you helping us keep a complex, multi-author program efficient and on schedule." - Medical Affairs Lead
Patient and provider preference studies were published in Cancer and ranked among the top 10% most downloaded articles in the year of launch.
Published burden and preference data supported payer communications and value articulation.
Evidence contributed to securing coverage across major commercial and public U.S. payers.